NORDHEALTH |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.7 NOK | -12.13% |
|
+2.06% | +19.76% |
| 03-05 | Transcript : Nordhealth AS, Q4 2023 Earnings Call, Mar 05, 2024 | |
| 03-05 | Nordhealth AS Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 51.69 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +19.76% | 242M | - | ||
| +4.71% | 32.47B | C | ||
| +16.61% | 7.45B | C- | ||
| +23.49% | 3.89B | B- | ||
| -15.80% | 3.17B | C- | ||
| -27.19% | 1.28B | B | ||
| -33.58% | 1.09B | - | ||
| -33.74% | 902M | - | ||
| +1.56% | 893M | C | ||
| -23.93% | 857M | - | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NORDH Stock
- Ratings Nordhealth
